ARTELO BIOSCIENCES, INC. Net Change in Cash
ARTELO BIOSCIENCES, INC. (ARTL) reported Net Change in Cash of $3.60 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-12
- ARTELO BIOSCIENCES, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was $9.67M.
- ARTELO BIOSCIENCES, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$1.59M.
- ARTELO BIOSCIENCES, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$1.62M, a 5885.71% decline year-over-year.
- ARTELO BIOSCIENCES, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was $28.00K.
- ARTELO BIOSCIENCES, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$5.27M.
- ARTELO BIOSCIENCES, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2021 was $4.49M.
- ARTELO BIOSCIENCES, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2020 was -$2.28M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 4 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $3.60M 10-Q · filed 2026-08-12 | ||||
| 2026-03-31 | $9.67M 10-Q · filed 2026-05-14 | ||||
| 2025-12-31 | -$1.74M 8-K · filed 2026-03-17 | ||||
| 2025-09-30 | -$618.00K 10-Q · filed 2025-11-12 | ||||
| 2025-06-30 | -$272.00K 10-Q · filed 2026-08-12 | ||||
| 2025-03-31 | -$1.59M 10-Q · filed 2026-05-14 | ||||
| 2024-12-31 | -$477.00K 8-K · filed 2026-03-17 | ||||
| 2024-09-30 | $1.54M 10-Q · filed 2025-11-12 | ||||
| 2024-06-30 | -$1.93M 10-Q · filed 2025-08-13 | ||||
| 2024-03-31 | -$1.62M 8-K · filed 2025-07-11 | ||||
| 2023-12-31 | -$4.07M 8-K · filed 2025-07-11 | ||||
| 2023-09-30 | -$4.25M 10-Q · filed 2024-11-12 | ||||
| 2023-06-30 | -$1.17M 10-Q · filed 2024-08-13 | ||||
| 2023-03-31 | $28.00K 10-Q · filed 2024-05-13 | ||||
| 2022-12-31 | -$5.27M 10-K · filed 2024-03-25 | ||||
| 2022-09-30 | -$5.03M 10-Q · filed 2023-11-13 | ||||
| 2022-06-30 | -$40.00K 10-Q · filed 2023-08-10 | ||||
| 2022-03-31 | -$1.81M 10-Q · filed 2023-05-11 | ||||
| 2021-12-31 | $5.53M 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | $803.00K 10-Q · filed 2022-11-08 | ||||
| 2021-08-31 | $4.49M 10-K · filed 2023-03-31 | ||||
| 2021-06-30 | $527.00K 10-Q · filed 2022-08-09 | ||||
| 2021-05-31 | $7.91M 10-Q · filed 2021-07-12 | ||||
| 2021-03-31 | $2.23M 10-Q · filed 2022-05-12 | ||||
| 2021-02-28 | $8.56M 10-Q · filed 2021-04-13 | ||||
| 2020-12-31 | $3.64M 10-KT · filed 2022-03-21 | ||||
| 2020-11-30 | $5.25M 10-Q · filed 2021-01-14 | ||||
| 2020-08-31 | -$2.28M 10-KT · filed 2022-03-21 | ||||
| 2020-05-31 | -$3.14M 10-Q · filed 2021-07-12 | ||||
| 2020-02-29 | -$2.44M 10-Q · filed 2021-04-13 | ||||
| 2019-11-30 | -$1.05M 10-Q · filed 2021-01-14 | ||||
| 2019-05-31 | -$50.98K 10-Q · filed 2020-07-13 | ||||
| 2019-02-28 | $119.90K 10-Q · filed 2020-04-13 | ||||
| 2018-11-30 | -$222.35K 10-Q · filed 2020-01-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B |